-
-
-
-
-
-
-
Amarin (AMRN) Retaining EU Rights 'The Right Thing to Do' - Cantor Fitzgerald
-
-
-
-
-
-
-
Amarin Corporation (AMRN) Expenses May Drive Expenses Higher but Vascepa Peak Sales Remains the Key for Investors - Cantor Fitzgerald
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Positive View on Amarin (AMRN) Following Final ICER Report
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Amarin Corporation (AMRN)
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Amarin (AMRN) Following Latest Vascepa Rxs
-
-
-
-
-
-
-
Amarin Corporation (AMRN) PT Raised to Street High $35 at Cantor Fitzgerald
-
-
-
-
-
-
-
Amarin (AMRN): AHA Showed OTC Fish Oil Inferior to FDA Approved Products and May Have Negative Effects - Cantor Fitzgerald
-
810 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

